Moderna's Melanoma Vaccine Clears a Clinical Test

Moderna and Merck's personalized melanoma vaccine produced a clear Phase 3 benefit, but the result answered the clinical question more convincingly than the commercial one. The combination of intismeran autogene and Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone in patients whose tumors had been completely removed.

The INTerpath-001 trial enrolled roughly 1,100 people with resected stage IIB to IV melanoma. After a median follow-up of 24.6 months, the recurrence-free survival hazard ratio was 0.58, with a 95% confidence interval of 0.45 to 0.75. The combination also reduced the risk of distant metastasis or death by 38%, with a hazard ratio of 0.62. Both primary comparisons were statistically significant.

Those are meaningful outcomes because melanoma that returns after surgery and spreads to the brain, lungs or liver becomes much harder to treat. Six melanoma specialists interviewed by CNBC described the result as a clinically important advance. Merck and Moderna said the overall safety profile was consistent with earlier studies and showed no new safety signal.

Why the market still sold Moderna

Moderna shares fell as much as 25% after partial results leaked before the full data release. The market had expected a strong result after a large rally tied to the cancer-vaccine program. Investors were also comparing the Phase 3 outcome with an earlier Phase 2 study that showed a larger reduction in recurrence risk at five years.

That comparison needs care. The Phase 3 trial included a broader mix of patients, including some with a lower baseline risk of recurrence. Different populations and follow-up periods mean the percentages are not interchangeable. A positive pivotal trial can therefore be clinically important while still falling short of the most optimistic expectations embedded in a stock price.

The timing of the effect adds another layer. During the first six months, recurrence risk was similar between the combination and Keytruda alone. In a prespecified sensitivity analysis after six months, the combination reduced recurrence or death by 58%. The vaccine is manufactured for each patient's tumor and can take about six weeks to produce, while the immune response may also need time to develop. Specialists cited that process as a possible explanation, but the timing analysis does not prove when the vaccine begins to work.

What remains unresolved

Overall survival data are not mature. The trial shows fewer recurrences and distant metastases, but it cannot yet establish how much longer patients live. It also did not compare the personalized vaccine strategy with immunotherapy given before surgery, an increasingly used approach for eligible patients.

Manufacturing is a second test. Each vaccine must be designed and produced for one patient, creating cost, capacity and turnaround-time challenges that do not exist for an off-the-shelf drug. Moderna and Merck have not disclosed the commercial manufacturing cost. The companies are engaging with regulators, but approval timing, pricing and real-world production capacity remain open questions.

For Moderna, intismeran is central to building a business beyond respiratory vaccines, so the stock is unusually sensitive to changes in expectations. For Merck, the program could extend the Keytruda franchise, but it is one asset inside a much larger oncology portfolio. The Phase 3 data strengthen the medical case. The investment case now depends on regulation, manufacturing scale, adoption and whether longer follow-up confirms the benefit.